As a family of transcription factors involved in the biogenesis of cholesterol, FAs and triglycerides, SREBPs are implicated in the pathogenesis of NAFLD/NASH and SREBP1 is the primary subtype expressed in the liver of mice and humans (28, 29). This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.